Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: To evaluate whether pyrosequencing (PS) improves the KRAS mutational status predictive value.
Patients & Methods: A retrospective analysis of KRAS mutations by PS and direct sequencing (DS) in 192 metastatic colorectal carcinomas (mCRCs), subgrouped in 51 KRAS mutated at PS and 141 KRAS wild-type at DS.
Results: DS failed to detect low-frequency KRAS mutations in four out of 51 mCRCs, whereas PS detected 12 additional low-frequency KRAS mutations in 141 mCRCs KRAS wild-type at DS. After reanalyzing by PS 97 KRAS wild-type tumors treated with anti-EGF receptor (EGFR) antibodies, nine additional mutations were revealed in nonresponders, whereas none of responders exhibited a KRAS-mutated genotype. Of note, KRAS-mutated tumors upon PS showed a worst progression-free survival after EGFR therapy. Finally, PS allowed the detection of additional NRAS, BRAF and exon 20 PIK3CA mutations mostly in KRAS wild-type mCRCs resistant to EGFR therapy.
Conclusion: PS detection of low-frequency mutations may improve the KRAS predictive value for EGFR therapy selection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon.13.233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research progress on predicting KRAS gene mutations in colorectal cancer by combining radiomics and multimodal medical imaging.
Front Oncol
August 2025
Department of Radiology, Guang an District People's Hospital of Sichuan Province, Guang an, Sichuan, China.
Colorectal cancer (CRC), a highly prevalent malignant tumor in clinical practice, poses a serious threat to human health. In 2015, the relevant guidelines issued by the United States clearly stipulated that only patients with the wild-type kirsten rat sarcoma viral oncogene homologue (KRAS) gene were recommended to receive epidermal growth factor receptor (EGFR) inhibitor treatment. Therefore, accurately predicting the status of the KRAS gene plays a crucial role in formulating scientific and reasonable treatment plans and improving prognosis.
View Article and Find Full Text PDFCombination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study.
J Cancer Res Ther
September 2025
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Objective: This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and without KRAS mutations.
Materials And Methods: We retrospectively collected data from patients with UCRLM, who received HAIC with HAICP or HAIC alone (oxaliplatin plus fluorouracil), including information on KRAS status (mutated, MUT; wild-type, WT) from a multicenter institutional database. Propensity score matching (PSM) was performed.
Structure-Based Discovery of Active Pan-KRas Inhibitors Targeting G12D Mutants by Enhanced Sampling Simulations.
J Phys Chem B
September 2025
State Key Laboratory of Porous Materials for Separation and Conversion, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, MOE Key Laboratory of Computational Physical Sciences, Department of Chemistry, Fudan University, Shanghai 200433, China.
Ras is a node protein in the classic tumor signaling pathway known as RAS-RAF-MEK. Mutations in Ras are reported to occur in approximately 19% of human cancers. Among them, the G12D mutation is one of the most prevalent mutations found in Ras.
View Article and Find Full Text PDFUBE2C promotes pancreatic tumorigenesis by KRAS stabilization via APC/C-mediated WDR76 degradation.
Cancer Lett
August 2025
Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of T
Bioinformatics-based association study revealed a strong positive correlation between UBE2C, an E2 ubiquitin-conjugating enzyme, and pancreatic cancer and patient survival. However, whether and how UBE2C plays a causal role in pancreatic tumorigenesis remains elusive. Here, we report that UBE2C functions as a promoter in this process.
View Article and Find Full Text PDFResults of a French screening campaign comparing clinical and molecular characteristics of interval colorectal cancers to cancers detected using a guaiac test.
Clin Res Hepatol Gastroenterol
September 2025
Service d'Hépato-Gastroentérologie, CHU Angers, 4 rue Larrey, 49933Angers Cedex 09, France. Electronic address:
Few studies have analyzed the biological characteristics of interval colorectal cancers (CRC) during a screening campaign. We included 98 patients of whom 46 had a screened cancer (SCG) and 52 an interval cancer (ICG). Microsatellite instability and gene mutation profiling were performed in 86 and 55 patients, respectively.
View Article and Find Full Text PDF